Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.5B
51M shares
52-week range
$25.36 – $43.18
19% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $201.6M | $230.8M | $206.5M | $274.3M | $330.4M | $399.2M | $465.3M | $534.5M |
| Cost of revenue | $54.5M | $60.5M | $57.2M | $68.5M | $84.4M | $98.9M | $117.8M | $136.8M |
| Gross profit | $147.1M | $170.3M | $149.3M | $205.9M | $245.9M | $300.4M | $347.5M | $397.7M |
| Gross margin | 73.0% | 73.8% | 72.3% | 75.0% | 74.4% | 75.2% | 74.7% | 74.4% |
| R&D | $34.7M | $41.2M | $43.1M | $48.5M | $57.3M | $73.9M | $96.2M | $90.2M |
| Operating income | −$17.1M | −$33.1M | −$44.2M | $55.2M | −$42.7M | −$26.7M | −$40.0M | −$3.4M |
| EBITDA | −$7.5M | −$21.5M | −$33.6M | $65.7M | −$29.5M | −$8.1M | −$18.5M | $16.2M |
| Net income | −$21.1M | −$35.2M | −$48.2M | $50.2M | −$46.5M | −$30.4M | −$44.7M | −$11.4M |
| Net margin | -10.5% | -15.2% | -23.3% | 18.3% | -14.1% | -7.6% | -9.6% | -2.1% |
| EPS (diluted) | -0.62 | -0.94 | -1.14 | 1.09 | -1.02 | -0.66 | -0.95 | -0.24 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $605M | $0.04 | $0.03–$0.04 | 6 |
| 2027 | $678M | $0.36 | $0.31–$0.40 | 6 |
| 2028 | $763M | $0.60 | $0.40–$0.77 | 5 |
| 2029 | $847M | $0.73 | $0.72–$0.74 | 1 |
Forward consensus · source: Financial Modeling Prep
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
www.atricure.comNo one on the platform currently holds ATRC.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 308,700 | $8.8M |
| Bridgewater Associatesas of 2026-03-31 | 33,517 | $956.2K |
No one on the platform has traded ATRC yet.
| $1.5B |
| — |
| LMATLeMaitre Vascular, Inc. | $96.00 | +0.36% | $2.2B | — |
| NVCRNovocure Ltd | $15.48 | +0.32% | $1.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 2.8× sales vs its 5.0× historical median P/S.
Fair value ≈ $51.50 · price $28.70 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$EW got FDA OK for heart clip; it enters a market led by $ATRC, adding competition but not changing the outlook much. https://notreload.xyz/xy/edwards-ecliptis-fda-clearance-challenges-atricure-atriclip/
View on StockTwits ↗$ATRC this is one of those classic cases of excellent company -> only a few hundred ST followers.
View on StockTwits ↗$ATRC these same conditions are basically true today. Reentering this very solid company
View on StockTwits ↗https://marketbeat.com/a/8650911/ $ATRC AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
View on StockTwits ↗$ATRC Ready and waiting for this one to rebound
View on StockTwits ↗$ATRC Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.00 • Reported revenue of $141.25M up 14.26% YoY • AtriCure projects full year 2026 revenue of $600M to $610M, Adjusted EBITDA of $80M to $82M, and adjusted earnings per share between $0.00 and $0.04, expecting continued positive cash flow.
View on StockTwits ↗$ATRC reports after the close, Estimize Consensus +0.01 EPS and +0.72M Revs compared to WS http://www.estimize.com/atrc/fq1-2026?utm_conten
View on StockTwits ↗$ATRC Share Price: $28.47 Contract Selected: Oct 16, 2026 $25 Calls Buy Zone: $4.25 – $5.25 Target Zone: $7.34 – $8.97 Potential Upside: 63% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ATRC $JNJ $MDT $HIMS $PFE https://www.marketbeat.com/instant-alerts/filing-oak-harvest-investment-services-makes-new-148-million-investment-in-atricure-inc-atrc-2026-04-18/ https://www.marketbeat.com/instant-alerts/filing-oak-harvest-investment-services-makes-new-148-million-investment-in-atricure-inc-atrc-2026-04-18/
View on StockTwits ↗$ATRC AtriCure (NASDAQ:ATRC) Stock Rating Upgraded by Freedom Capital https://marketwirenews.com/stock/atrc/news/atricure-nasdaq-atrc-stock-rating-upgraded-by-freedo-6407586195622607.html?utm_source=stocktwits
View on StockTwits ↗$ATRC Share Price: $28.79 Contract Selected: Oct 16, 2026 $25 Calls Buy Zone: $3.82 – $4.73 Target Zone: $7.07 – $8.64 Potential Upside: 75% ROI Time to Expiration: 197 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ATRC Medinice (ICE.WA) – The $ATRC Disruptor? FDA Milestones. Keep an eye on this Polish medtech player disrupting surgical ablation & LAAO: • CoolCryo (FDA Cleared!): Uses Liquid Nitrogen, not nitrous oxide. 4-6x faster, better transmurality, works on beating heart. Tier-1 players already in the data room for M&A. • AtriClamp (LAAO Game Changer): Just filed FDA 510(k) Q-Sub for a polymer-based LAA clip. One LOI is already signed • 100% MRI Safe: Metal-free (unlike AtriClip/FLEX-Mini). No artifacts, perfect post-op diagnostics. • Unique Deployment: Extendable/sliding mechanism (not simple snap-fit) with a solid patent wall. • Scalability: Mass-produced via injection molding. Low COGS, massive margins. With a market cap <$100M, this is a textbook buyout target for $BSX or $MDT. Anyone else tracking this? #Medtech #Cardiology #ATRC #BSX #FDA #LAAO
View on StockTwits ↗$PLAB $KMI $ATRC $BX $LTH watch the charts closely today as intraday patterns hint at rebounds and breakouts bottom line $BX looks most juicy https://stocksrunner.com/news/2026-02-25-intraday-technical-patterns-reveal-key-short-term-opportunities
View on StockTwits ↗$ATRC Share Price: $33.38 Contract Selected: Jul 17, 2026 $35 Calls Buy Zone: $5.95 – $7.35 Target Zone: $11.08 – $13.54 Potential Upside: 76% ROI Time to Expiration: 146 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ATRC (+3.7% pre) AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates https://ooc.bz/l/93657
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.